Navigation Links
Newbridge Securities Corporation Forms BioVentures Division
Date:2/17/2009

Newbridge Expands its Presence in the Biotech Industry

FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). NBV is dedicated to providing investment banking services for the biotech industry and related investment opportunities for institutional and sophisticated individual investors.

We are pleased to announce Christopher Carra as the Managing Director of NBV. Mr. Carra has been a registered representative in the securities industry for over 16 years, primarily focused in the biotech sector. Mr. Carra has been involved in several private placements and initial public offerings for biotech companies, and is a founding member of NBV. Prior to joining Newbridge in 2005, Mr. Carra worked at several private-client focused firms, most recently Oppenheimer & Co., where he worked from 2000-2005 as a senior vice president.

Please visit the BioVentures website; it can be accessed through www.newbridgesecurities.com or www.investbiopharma.com.

"We are extremely excited to add NBV as a focus to our already diversified suite of businesses," said Guy S. Amico, Newbridge's president. "In addition, having powerful advisors, such as Dr. David Sherris, Ph.D., on the Scientific Advisory board will lend top-level credibility and research to enhance our success rate for our Institutional and Private Client Group clients."

About Newbridge

Newbridge Securities Corporation provides full service securities brokerage and investment banking services to a broad based group of individuals and corporate clients. Comprised of a committed and experienced team of financial service professionals, we seek to empower our clients to build and preserve wealth by providing superior financial services and products.

For more information on NBV, contact Christopher Cara at 561.391.1220 (email at ccara@newbridgesecurities.com) or visit our website at www.newbridgesecurities.com.


'/>"/>
SOURCE Newbridge Securities Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission
2. deCODE Sells Auction Rate Securities
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
5. Isolagen to Present at the JMP Securities Healthcare Focus Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
10. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):